Immunotherapy after surgery may keep melanoma at bay
NCT ID NCT02362594
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether giving the immunotherapy drug pembrolizumab after surgery helps prevent melanoma from returning in people with high-risk stage III melanoma. About 1,000 participants received either pembrolizumab or a placebo for up to a year. The main goal was to see if the drug delays recurrence or death. Those whose cancer returned could receive pembrolizumab later.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can new drug cocktails reawaken the immune system against melanoma?
- Could a Six-Month exercise and diet plan shield muscle during melanoma treatment?
- Quitting before the knife: which Stop-Smoking aid works best for cancer patients?
- Can a One-Two punch of immune boosters revive cancer treatment?
- Can a modified herpes virus turn the tide against advanced cancer?
- Can your genes predict your melanoma risk?